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Use of Prostaglandin E1 in Crossmatch-Negative Liver Transplant 
Recipients Treated With FK 506 
S. Takaya, O. Bronsther, K. Abu-Elmagd, H. Ramos, J.J. Fung, S. Todo, and T.E. Starzl 
ALTHOUGH the overall strategy for the use ofFK 506 
remains the same as when this T-cell-directed drug 
was introduced clinically in 1989,1,2 there have been mod-
ifications. As with cyclosporine (CyA), the nephrotoxicity 
of FK 506 imposes a dose ceiling, necessitating its use in 
drug cocktails that include adrenal corticosteroids. We 
recently reported that liver transplant recipients with the 
immunological disadvantage of a positive cytotoxic cross-
match with their donors3 could have their prognosis con-
verted to that in crossmatch-negative cases when FK 506 
was combined with high induction doses of prednisone. 4 A 
subgroup of these patients who also were treated periop-
eratively with prostaglandin EI (PGE!) had superior renal 
function, suggesting an amelioration of nephrotoxicity by 
PGEI without a loss of immunosuppression, or conceiv-
ably with a gain. In the trial reported here, PGE] was 
evaluated in crossmatch-negative liver recipients. 
METHODS 
Case Material 
Primary adult liver recipients (> 16 years of age) from three 
consecutive periods beginning June 10, 1990, were entered into 
the study, with exclusion only if there was a positive cytotoxic 
crossmatch or if the patient had renal failure pre transplantation. 
Renal failure was defined by dialysis dependence or by multiple 
preoperative serum creatinines of at least 2 mgldL. Patients in all 
three study groups (Table I) were started postoperatively on 20 
mgld prednisone after being given a single log bolus of methyl-
prednisolone intraoperatively. The variables were in FK 506 (high 
vs low induction dose) and in PGE] (inclusion or not). 
FK 506 dosing was controlled throughout by measurement of 
plasma levels.s Trough levels over 1 nglmL were considered to 
reflect a potential toxicity at all times after the first week. The 
starting daily intravenous FK 506 doses of 0.1 mg/kgld in group I 
and half this amount in groups 2 and 3 were given by 24-hour 
continuous infusion. When the conversion to oral FK 506 was 
made (Fig I), dosing as close to 0.3 mglkgld was attempted. 
However, it usually was not possible to give this much of the drug 
without driving up the plasma trough levels beyond the desired I 
to 2 nglmL range. The heavy initial FK 506 dosing as a policy in 
group 1 was reflected in significantly higher plasma levels than in 
either group 2 or 3 for each of the first 4 weeks and the total 
month. 
There were no significant FK 506 dosage or plasma level 
differences between groups 2 and 3 (Fig I). Patients in group 3 
were given intravenous PGE] (Prostin VR) beginning during the 
operation or after its completion. The starting dose was 0.2 
J.£g/kg/h which was increased to 0.6 J.£glkglh and maintained there 
for the next 5 to 7 days unless hypotension or cardiovascular 
instability interdicted the increase. When the patients resumed 
diet, they were switched to the oral PGE] analog misoprostol 
(Cytotec) at doses of 400 to 800 J.£gld in four divided doses. Two of 
the 41 patients in group 3 could not complete the PGE] therapy, 
Table 1. Patient Profile and Outcome 
Group 1 Group 2 Group 3 
Number 124 38 41 
Date began 6/10/90 8/27/91 11/1/91 
FK 506 (mg/kg/d) 0.1 0.05 0.05 
Prednisone (mg/d) 20 20 20 
PGE, No No Yes 
Age 44.9 ± 1.4 51.9 ± 1.7 50.4 ± 1.6 
Malelfemale 76/48 27/11 24/17 
Liver disease 
Idiopathic 16 3 6 
Alcoholic 25 6 13 
Viral 24 19 11 
Cholestasis 29 5 4 
Malignancy 17 5 4 
Fulminant hepatic failure 5 0 1 
Miscellaneous 8 0 2 
Retransplantation within 1 12 3 5 
month 
Death in 1 month 4 1 2 
(Patients died after (1 ) (0) (2) 
retransplant) 
Graft survival at 1 month 109 (87.9%) 34 (89.5%) 36 (87.8%) 
Patient survival at 1 month 120 (96.8%) 37 (97.4%) 39 (95.1%) 
Cause of graft failure 
Preservation injury 3 3 2 
Technical 8 3 
Infection 4 0 0 
one because of poor graft function, norepinephrine dependence, 
and the need for retransplantation after 7 days. Therapy was 
foreshortened in the other because of a fatal myocardial infarction 
3 days posttransplantation. These two patients were included in 
survival calculations but excluded from the analyses of renal 
function. 
Diagnosis and Treatment of Rejection 
A positive biopsy was a condition for the diagnosis of liver 
allograft rejection. The histopathological grading system of rejec-
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Fig 1. Dose of intravenous and 
oral FK 506, plasma trough lev-
els, and serum creatinine levels 
in patients surviving 30 days (ex-
cluding hemodialysis patients). 
The mean dose of group 1 was 
significantly higher than those of 
group 2 or group 3 (P < .001). 
The mean FK 506 plasma level 
of group 1 for the first 30 days 
was significantly higher than 
those of group 2 or group 3 (P < 
.001). No statistically significant 
difference was observed in the 
dosage of intravenous and oral 
FK 506 regimens or plasma FK 
506 trough levels between group 
2 and group 3. The mean values 
of serum creatinine in group 3 
were significantly lower than 
those of group 1 patients at the 
second (P = .22), third (P = 
.0046), and fourth postoperative 
weeks (P = .0004). Values are 
expressed as means ± SE. 
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tion, as developed by Demetris et al,6 was: grade I (early or 
consistent with rejection), grade 2 (mild), grade 3 (moderate), and 
grade 4 (severe). In addition to the biopsy, a Doppler ultrasound 
also was required with intact liver vascularization and no dilata-
tion of intrahepatic bile ducts. A cholangiogram and an arterio-
gram were performed if the ultrasound findings were equivocal. 
One gram of intravenous methylprednisolone was given for biop-
sy-proven rejection, followed, if necessary, by an additional5-day 
"burst" of methylprednisolone, beginning with 200 mg the first 
day, followed by a daily decrease of 40 mg until 20 mg/d was 
reached on the sixth day. If rejection persisted, a 3- to 5-day 
course of 5 to 10 mg/d of OKT3 was given. 
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Statistical Analysis 
Biochemical parameters were followed for 30 days and included 
hepatic and renal function, and dosage and plasma trough levels of 
FK 506. Statistical analysis was performed by Mann-Whitney U 
test or chi-square testing with Yates correction. Results were 
expressed as means ± SEM. 
RESULTS 
Patient and Graft Survival 
Patient survival was essentially the same in all groups 
(95.1 % to 97.4%), as were the graft survival rates (87.5% to 
Table 2. Episodes of Acute Cellular Rejection and Supplemental Immunosuppression in Grafts Surviving 30 Days 
Group 1 Group 2 Group 3 PValue 
Number of primary grafts 109 34 36 
Number of grafts with rejection in month 1 58 (53.2%) 21 (61.8%) 16 (44.4%) NS 
Onset of first episode (day)' 9.4 ± 0.8 8.8 ± 0.9 10.7 ± 2.1 NS 
Number of rejection episodes 
1 32 (29.4%) 12 (35.3%) 11 (30.6%) NS 
2 19 (17.4%) 8 (23.5%) 3 (8.3%) NS 
2:3 7 (6.4%) 1 (2.9%) 2(5.6%) NS 
Supplemental immunosuppression 
1 g methylprednisolone 0.55 :+:: 0.07t 0.97 ± 0.15 0.86 ± 0.13 .012 
Steroid cycling 16 (14.7%)* 11 (32.4%) 8 (22.2%) .024 
OKT3 4 (3.7%) 2 (5.9%) 0(0%) NS 
T. Bilirubin at first month (mg/dL) 1.85 ± 0.29 1.26 ± 0.14 1.23±0.17 NS 
>Biopsy verified, mean ± SE. 
t P = .012 vs group 2, P = .044 vs group 3. 
*p = .024 vs group 2. 
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Table 3. Evaluation of Biopsy Specimens in Grafts 
Surviving 30 Days 
Group 1 Group 2 Group 3 
Number of primary grafts 109 34 36 
Total number of biopsy 179 53 52 
specimens* 
Biopsy specimens per graft 1.64 1.56 1.44 
No ACRt 88 (49.2%) 20 (37.7%) 27 (51.9%) 
Consistent with or early 15 (8.4%) 9 (17.0%) 7 (13.5%) 
ACR (grade 1) 
Mild ACR (grade 2) 59 (33.0%) 19 (35.8%) 13 (25.0%) 
Moderate ACR (grade 3) 14 (7.8%) 5 (9.4%) 5 (9.6%) 
Severe ACR (grade 4) 3 (1.7%) 0 0 
"During the first 30 days. 
t AeR, Acute cellular rejection. 
89.5%) and the need for retransplantation (Table 1). Liver 
grafts were lost to various causes (Table 1). Primary 
nonfunction leading to retransplantation was observed in 
three patients in group 1 (2.4%), three patients in group 2 
(7.9%), and two patients in group 3 (4.8%). Sepsis caused 
four deaths in group 1 but was not responsible for any 
mortality in groups 2 and 3 (Table 1). 
Incidence and Treatment of Rejection 
Although no grafts were lost to acute rejection in any ofthe 
groups (Table 1), rejection was diagnosed within 1 month 
in 53%, 62%, and 44% of the recipients in groups 1 through 
3, respectively. The time of onset, frequency, and his-
topathological severity of these episodes were also similar 
in the three groups (Tables 2 and 3). However, the mean 
number of steroid boluses given per patient during the first 
30 days was 0.55 for group 1, significantly lower than 0.97 
for group 2, and 0.86 for the group 3. In addition, the high 
induction dose of FK 506 (group 1) significantly reduced 
the need for steroid recycling vs group 2 (P = .024) but not 
group 3 (P = .27). Differences in OKT3 usage among the 
groups were not statistically significant; actually no patient 
in group 3 required OKT3 in the first 30 days (Table 2). 
2383 
Renal Function 
Hemodialysis was required in 13.8% of the group 1 pa-
tients, 14.7% of the group 2 patients, and in only one 
(2.8%) of the 41 patients in group 3 (Table 4). The 
exceptional patient in group 3 had two treatments for 
volume overload on the second and third postoperative 
days with slow continuous ultrafiltration with Dianeal 
(Table 4). By the end of the first month, 9.2%, 11.8%, and 
0% of the patients in groups 1 through 3, respectively, 
were still on hemodialysis (Table 4). 
Even excluding those patients on dialysis, the mean 
serum creatinine during the first 30 days was elevated in all 
groups. These levels decreased slowly after the second 
postoperative week in group 3 (Fig 1), but they remained 
significantly higher in groups 1 and 2 relative to group 3 
(Table 4). The beneficial kidney-protective effect of PGE I 
in the group 3 patients vs those in group 2 was most 
pronounced in those recipients who were given <15 units 
of packed red blood cells vs those with a blood transfusion 
requirement greater than this (P = .0087) (Fig 2). 
DISCUSSION 
The pathogenesis of FK 506 nephrotoxicity and other side 
effects has been thought from the outset to be similar to 
that of CyA.2,7-9 With both drugs, a decrease in effective 
renal plasma flow and glomerular filtration rate and an 
increase in renal vascular resistance may be associated 
with the secretion of endothelin-l JO or thromboxane A211 
and other products of arachidonic acid metabolism. Be-
cause prostaglandins of series 12, Eu and E2 are potent 
vasodilators and modulators of tone in the pre- and post-
glomerular arterials, they were evaluated for the pharma-
cological interdiction of these undesirable effects ofCyA in 
the studies by Makowka et al12 and Ryffel et al. 13 In 
Makowka's original study, CyA blood levels were not 
obtained. 
In the present investigation, in which this supporting 
data ofFK 506 were available, the dose and plasma levels 
were essentially the same in groups 2 and 3, making it 
possible in these two groups to make a discriminative 
Table 4. Hemodialysis and Renal Function in Primary Grafts Surviving More Than 30 Days 
Group 1 Group 2 
Number of patients 109 34 
Hemodialysis for first month 15 (13.8%) 5 (14.7%) 
Hemodialysis at first month 10 (9.2%) 4 (11.8%) 
Preoperative creatinine (mg/dL) 0.72 ± 0.04 1.03 ± 0.06 
Creatinine at 1 week' 1.41 ± 0.09 1.57 ± 0.16 
Creatinine at 2 weeks 1.57 ± 0.08 1.50 ± 0.13 
Creatinine at 3 weeks 1.63 ± 0.08 1.48 ± 0.11 
Creatinine at 4 weeks 1,68 ± 0.07 1,53 ± 0.12 
Creatinine 2:2.0 mg/dL at first month 18 (19.1%) 3 (10.3%) 
'Patients required two times of slow continuous ultrafiltration with Dianeal. b, c, d; Group 1 vs group 3. 
tGroup 1 vs group 2, group 1 vs group 3. 
'Excludes the hemodialysis patients, mean ± SE. 
§Group 1 vs group 3. 
Group 3 PValue 
36 
1 (2.8%)* NS 
0(0%) NS 
1.06 ± 0,06t <.001 
1.42 ± 0.12 NS 
1.24 ± 0.08§ .022 
1.25 ± 0.08§ .0046 
1.31 ± 0.09§ .0004 
3(8.6%) NS 
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Fig 2. Division of blood usage 
during liver transplantation in 
group 2 (n = 23) and group 3 (n 
= 19) with low transfusion group 
[<15 units of packed red blood 
cells (PRBC)] and high transfu-
sion group (215 units of PRBC) 
(n = 6 in group 2, n = 16 in group 
3, excluding hemodialysis pa-
tients). In the lower transfusion 
group, the mean creatinine in 
group 3 was significantly lower 
than that of group 2 for the first 
30 days (1.48 ± 0.08 mg/dL vs 
1.20 ± 0.05 mg/dL, P = .0087). 
Values are expressed as mean 
± SE. 
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assessment of the kidney-sparing effect of PGE,. The 
PGE, appeared to have substantially reduced the FK 506 
nephrotoxicity. This was particularly evident in patients 
with the least troublesome perioperative courses, as re-
flected by their minimum needs for blood transfusion. In 
contrast, the value of PGE, was obscured in patients who 
required more than I5-unit transfusions. 
The reduced nephrotoxicity in the PGE,-treated group 3 
was reflected not only in the better average postoperative 
renal function, but also by the nearly complete elimination 
of the need for posttransplant dialysis. Only a single 
patient of the 36 in group 3 required such support, and in 
this instance the dialysis intervention for correction of 
volume overload was very brief. It has long been known 
that the liver recipient is especially vulnerable to renal 
failure, partly because occult renal dysfunction so often 
already is present in the preoperative period. '4 Causes of 
further renal damage perioperativeiy are multifactorial 
and, in addition to suspect immunosuppressive drugs, 
include cardiovascular instability, endotoxemia, and neph-
rotoxic antibiotics. In spite of the complexity of this 
background in the liver transplant recipients, our conclu-
sion that PGE I protects the kidney from concomitantly 
administered nephrotoxic drugs was essentially the same 
as that reached by Moran et ailS in less complicated 
clinical renal transplant trials. 
The second and less clearly resolved question in this 
study was whether PGE, altered the efficacy of FK 506 or 
was itself inherently immunosuppressive. There was no 
clear evidence for either possibility. In the low FK 506 
dose groups 2 and 3, in which the therapeutic variable was 
PGE I , the presence or absence of the PGE I did not 
obviously influence the rate of rejection, the use of sup-
plemental steroids or adjuvant immunosuppressive mea-
sures, or the doses and plasma levels of FK 506. In both 
groups 2 and 3, the need for augmented steroids was 
significantly greater than in the patients of group 1, who 
were started on high doses of FK 506. 
Thus, this study, as well as our earlier one of patients 
who received crossmatch-positive livers,4 has shown that 
the greatest value of PGE I is amelioration of nephrotoxic-
ity. However, we emphasize that previous workers in 
controlled animal experiments have shown obtundation of 
cellular'6.'7 or humoral responsiveness, '8 or both. '9-21 We 
believe that an immunosuppressive effect was too subtle to 
be detected under the complex circumstances of these 
liver transplantation cases. 
REFERENCES 
1. Starzl TE, Todo S, Fung J, et al: Lancet 2:1000, 1989 
2. Todo S, Fung JJ, Starzl TE, et a1: Ann Surg 212:295, 1990 
3. Takaya S, Bronsther 0, Iwaki Y, et al: Transplantation 
53:400, 1992 
4. Takaya S, Iwaki Y, Starzl TE: Transplantation 54:927,1992 
5. Tamura K, Kobayashi M, Hashimoto K, et al: Transplant 
Proc 19(5uppI6):23, 1987 
6. Demetris AI, Qian S, Sun H, et al: Am J Surg Pathol 14:49, 
1990 
PGE1 IN LIVER TRANSPLANTS WITH FK 506 
7. Kusne S, Dummer JS, Singh N, et al: Medicine 67:132,1988 
8. Starzl TE, Fung JJ: JAMA 263:2686, 1990 
9. Nalesnick M, Lai HS, Murase N, et al: Transplant Proc 
22:87, 1990 
10. Moutabarrik A, Ishibashi M, Fukunaga, et al: Transplant 
Proc 23:3133, 1991 
11. Rogers TS, Elzinga L, Bennet WM, et al: Transplantation 
45:153,1988 
12. Makowka L, Lopatin W, Gilas T, et al: Clin Nephrol 
25:S89, 1986 
13. Ryffel B, Donatsch P, Hiestand P, et al: Clin Nephrol 
25:S95, 1986 
2385 
14. Klintmalm GBG, Klingensmith WC III, Iwatsuki S, et al: 
Radiology 142:199, 1982 
15. Moran M, Mozes MF, Maddux MS, et al: N Eng! J Med 
322: 1183, 1990 
16. Chonaib S, RobbRJ, Welte K, etal: J Clin Invest 80:333, 1987 
17. Makoul GT, Robinson DR, Bhalla AK, et al: J Immunol 
134:2645, 1985 
18. Makowka L, Miller C, Chapchap P, et al: Ann Surg 
206:482, 1987 
19. Rappaport RS, Dodge GR: J Exp Med 155:943, 1982 
20. Snyder DS, Beller 01, Unanue ER: Nature 299:163, 1982 
21. Weir MR, Wang Li X, Gomolka D, et al: Transplantation 
52:1053, 1991 
